Masimo Co. (NASDAQ:MASI) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $179.67.

A number of equities research analysts recently issued reports on MASI shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company upped their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler lifted their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd.

Masimo Stock Down 2.0 %

MASI opened at $165.30 on Wednesday. The company has a market capitalization of $8.85 billion, a PE ratio of 114.00 and a beta of 1.01. The firm has a 50-day simple moving average of $163.89 and a two-hundred day simple moving average of $136.78. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a 52 week low of $101.61 and a 52 week high of $180.97.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 earnings per share. Analysts forecast that Masimo will post 4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. grew its stake in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. HHM Wealth Advisors LLC raised its position in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 125 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Masimo in the 2nd quarter worth $109,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Masimo during the 3rd quarter worth $118,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.